Shimokawa Tomoki, Kumamaru Hiraku, Motomura Noboru, Nishi Hiroyuki, Nakajima Hiroyuki, Kamiya Hiroyuki, Tabata Minoru, Okamoto Kazuma, Hosoba Soh, Saiki Yoshikatsu, Sakaguchi Taichi
Scientific Registry Committee of Japanese Society of Minimally Invasive Cardiac Surgery, Osaka, Japan.
Department of Cardiovascular Surgery, Teikyo University, 2-11-1, Kaga, Itabashi-ku, Tokyo, 173-8606, Japan.
Gen Thorac Cardiovasc Surg. 2025 Feb;73(2):88-95. doi: 10.1007/s11748-024-02066-2. Epub 2024 Jul 31.
Although minimally invasive cardiac surgery (MICS) procedures are widely performed throughout Japan, nationwide data regarding treated cases are limited. Up-to-date results for cardiovascular surgery are vital for quality control in clinical practice. Presented here is the 2021 annual report based on data from the Japan Cardiovascular Surgery Database (JCVSD).
Records noted in the JCVSD of patients who underwent mitral valve surgery, aortic valve replacement (AVR), coronary artery bypass grafting (CABG), atrial septum defect (ASD) closure, or cardiac tumor resection via right or left minithoracotomy, as well as thoracoscopic- or port-assisted, or robotic-assisted approaches, in 2021 were examined. Perioperative parameters including mortality and morbidity was evaluated.
The 30-day and in-hospital mortalities for isolated mitral valve repair (n = 1211) were 0.1% and 0.2%, respectively, while those for all mitral valve repair (n = 2017) were 0.05% and 0.2%, respectively. More than 100 facilities were found to perform fewer than five MICS mitral valve surgery cases per year. As for MICS-AVR, 30-day and in-hospital mortalities for isolated AVR (n = 818) were 0.5% and 0.5%, respectively, while those for all AVR (n = 987) were 0.6% and 1.1%, respectively. Additionally, those for MICS-CABG (n = 400) were 0.8% and 0.5%, respectively. Those for ASD (n = 183) and cardiac tumor (n = 96), were 0.5% and 0.5%, respectively, and 0% and 1.0%, respectively.
This is the first report of MICS results of procedures performed in Japan based on the 2021 JCVSD data. Additional results obtained with a similar data collection method are expected and details on MICS are being collected starting 2024.
尽管微创心脏手术（MICS）在日本各地广泛开展，但关于治疗病例的全国性数据有限。心血管手术的最新结果对于临床实践中的质量控制至关重要。本文展示的是基于日本心血管手术数据库（JCVSD）2021年数据的年度报告。
对2021年在JCVSD中记录的通过右或左小切口开胸、胸腔镜辅助、端口辅助或机器人辅助方法进行二尖瓣手术、主动脉瓣置换术（AVR）、冠状动脉旁路移植术（CABG）、房间隔缺损（ASD）封堵或心脏肿瘤切除术的患者记录进行检查。评估包括死亡率和发病率在内的围手术期参数。
单纯二尖瓣修复术（n = 1211）的30天和住院死亡率分别为0.1%和0.2%，而所有二尖瓣修复术（n = 2017）的30天和住院死亡率分别为0.05%和0.2%。发现有100多家机构每年进行的MICS二尖瓣手术病例少于5例。至于MICS-AVR，单纯AVR（n = 818）的30天和住院死亡率分别为0.5%和0.5%，而所有AVR（n = 987）的30天和住院死亡率分别为0.6%和1.1%。此外，MICS-CABG（n = 400）的30天和住院死亡率分别为0.8%和0.5%。ASD（n = 183）和心脏肿瘤（n = 96）的30天和住院死亡率分别为0.5%和0.5%，以及0%和1.0%。
这是基于2021年JCVSD数据的日本MICS手术结果的首次报告。预计将通过类似的数据收集方法获得更多结果，并且从202年开始收集有关MICS的详细信息。
